Salarius Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Salarius Pharmaceuticals, Inc.

Jan-07	Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics GlobeNewswire
Dec-19	Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting GlobeNewswire
Dec-18	Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform GlobeNewswire
Dec-01	Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study GlobeNewswire
Nov-19	Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol "SLRX" GlobeNewswire
Nov-13	Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger GlobeNewswire
Oct-13	Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements GlobeNewswire
Sep-09	Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement GlobeNewswire
Aug-14	Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split GlobeNewswire
Jul-14	Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard GlobeNewswire
Jul-09	Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.